Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

66.09USD
29 Jul 2016
Change (% chg)

$1.37 (+2.12%)
Prev Close
$64.72
Open
$65.27
Day's High
$66.40
Day's Low
$65.15
Volume
5,828,272
Avg. Vol
8,181,438
52-wk High
$71.51
52-wk Low
$45.45

Latest Key Developments (Source: Significant Developments)

AbbVie CEO says no longer looking for a big acquisition: Conf Call
10:24am EDT 

: Abbvie Expects Mid Teen percentage prescription volume growth for humira: conf call . Abbvie ceo says indirect biosimilar competition for humira has been as expected in the quarter: conf call . Abbvie expects 2016 revenue of about $26 billion : conf call . Abbvie ceo says he remains confident on the ip protection on humira: conf call . Abbvie ceo says will consider opportunities that are complementary to their portfolio, but is no longer pursuing a big acquisition : conf call Further company coverage: [ABBV.N] (Bengaluru Newsroom +1-646-223-8780).  Full Article

Abbvie Q2 adjusted EPS $1.26
7:38am EDT 

Abbvie : FY 2016 earnings per share view $4.75 -- Thomson Reuters I/B/E/S . Reports Second Quarter 2016 financial results . Q2 adjusted earnings per share $1.26 . Q2 GAAP earnings per share $0.98 . Q2 revenue $6.45 billion versus I/B/E/S view $6.2 billion . Q2 earnings per share view $1.20 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $4.73 to $4.83 . Sees FY 2016 GAAP earnings per share $3.82 to $3.92 .Q2 total Humira sales $4,149 million versus. $3,537 million last year.  Full Article

AbbVie initiates late stage study of venetoclax in patients with relapsed or refractory multiple myeloma
Thursday, 28 Jul 2016 05:30pm EDT 

Abbvie Inc : Venetoclax is being developed by abbvie and genentech, a member of roche group .Abbvie announces initiation of phase 3 study of venetoclax in patients with relapsed or refractory multiple myeloma.  Full Article

X-Chem, AbbVie enter into drug discovery partnership
Tuesday, 26 Jul 2016 08:15am EDT 

X-Chem Inc : X-Chem and abbvie enter into multi-target drug discovery partnership .Chem - financial terms were not disclosed..  Full Article

Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
Monday, 25 Jul 2016 04:00am EDT 

Abbvie Inc : CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C with compensated cirrhosis (child-pugh a) .Says VIEKIRAX with RBV is currently approved in European Union for GT4 patients with compensated cirrhosis for 24 weeks.  Full Article

Ablynx CEO sees potential multibillion-dollar opportunity for drug
Thursday, 7 Jul 2016 04:22am EDT 

Ablynx CEO Edwin Moses told Reuters: Sales opportunity for vobarilizumab could be in "billions" of dollars in rheumatoid arthritis & other diseases . AbbVie will decide later in 2016 whether to license vobarilizumab, after second RA trial results expected in August Further company coverage: [ABLX.BR] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

Biogen and Abbvie's multiple sclerosis drug approved in EU
Tuesday, 5 Jul 2016 08:00am EDT 

Abbvie Inc :Biogen and Abbvie's once-monthly Zinbryta™ (Daclizumab) approved in European Union for treatment of multiple sclerosis.  Full Article

Biogen and AbbVie's drug approved in EU
Tuesday, 5 Jul 2016 08:00am EDT 

Biogen Inc : Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis . Zinbryta significantly reduced multiple measures of disease activity in patients with relapsing forms of MS .Targeted mechanism of action of zinbryta did not cause broad, prolonged depletion of studied immune cell types.  Full Article

Abbvie announces fourth breakthrough therapy designation granted by FDA
Wednesday, 29 Jun 2016 07:30am EDT 

AbbVie Inc : Abbvie announces fourth breakthrough therapy designation granted by the U.S. Food and drug administration (FDA) for ibrutinib (imbruvica) for chronic graft-versus-host-disease (CGVHD), a rare condition with limited treatment options . FDA also granted therapy orphan drug designation (ODD) for condition . Imbruvica is jointly developed and commercialized by Pharmacyclics LLC, an Abbvie company and Janssen Biotech Inc .Versus-Host-Disease (CGVHD), a rare condition with limited treatment options.  Full Article

Infinity regains worldwide rights to duvelisib; ends collaboration with AbbVie
Tuesday, 28 Jun 2016 06:55am EDT 

Infinity Pharmaceuticals Inc : Infinity undertakes restructuring of workforce . Infinity will also reduce its workforce by 58 percent . Says neither infinity nor abbvie have future financial obligations to other party . Exploring strategic options for program that could enable submission of global regulatory applications, commercialization for duvelisib . Says will not proceed with phase 1b/2 study of duvelisib in combination with venetoclax . Says ipi-549 is only investigational pi3k-gamma inhibitor in clinical development . Continuing to focus on filing nda for duvelisib with u.s. Food and drug administration (fda) in q4 of 2016 . Plans to seek feedback on dynamo data from fda . Strategic decisions include closing bravura, a phase 3 study of duvelisib, contempo, a phase 1b/2 study of duvelisib . Also expects to report topline data from duo, predicated on results of an interim analysis, in q3 of 2016 .Infinity regains worldwide rights to duvelisib following mutual agreement with abbvie to end collaboration.  Full Article

Photo

Drugmaker AbbVie bumps up profit forecast on strong Humira sales

AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.